Weyerhaeuser Stock Rated Hold by Argus as Housing Sector Remains Weak
Argus analyst Marie Ferguson maintained a Hold rating on Weyerhaeuser Company (NYSE:WY) on May 28, citing the company's challenges in the current economic environment, with no price target provided. Ferguson's remarks suggest that Weyerhaeuser's profits are directly related to the new-housing market, which has tanked due to high borrowing costs and a weak economy.
The increase in existing home sales has only made the oversupply situation worse, which was caused by the slowdown in development over the past two years. Although a return to positive yearly earnings growth is possible this year, analysts at Argus predict that any improvement will be evaluated against a low starting point. The housing market is expected to remain weak for the majority of 2025, trailing behind the broader economic recovery. Given this, Argus predicts that Weyerhaeuser Company (NYSE:WY) might not establish a solid foundation until 2026.
One of the biggest private owners of timberlands in North America, Weyerhaeuser Company (NYSE:WY) is a US-based REIT that manages around 10.4 million acres in the United States alone, with additional properties in Canada under long-term licenses.
While we acknowledge the potential of WY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than WY and that has 100x upside potential, check out our report about the cheapest AI stock.
Read More: and
Disclosure: None.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
38 minutes ago
- Business Wire
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte's monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofibrosis (MF) and essential thrombocythemia (ET). Under the terms of the Master Collaboration Agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the next-generation sequencing (NGS) technology and the Illumina NextSeq 550Dx platform as part of QIAGEN's partnership with Illumina (NASDAQ: ILMN) to leverage its NGS diagnostic platforms for patient testing by laboratories worldwide. QIAGEN will support regulatory submission processes and market access activities across the United States, European Union and Asia-Pacific regions. Myeloproliferative neoplasms are a group of diseases representing about 40% of hematological malignancies, characterized by chronic accumulation of different mature blood cell types in blood. Identifying genomic aberrations in clinically relevant biomarkers like CALR are shown to be key, especially in MPNs. Incyte is at the forefront of developing novel therapies, including INCA033989 for patients with mutCALR ET or MF, that target only malignant cells, sparing normal cells. The use of companion diagnostics helps guide clinicians in making treatment decisions that can lead to better patient outcomes. 'Following our presentation of positive, late-breaking data from our first-in-class mutCALR-targeted antibody at EHA, we are excited to announce this partnership with QIAGEN, which will facilitate CALR testing for patients with MPNs on a global basis. The development of companion diagnostics for mutCALR, coupled with the potential for new medicines to selectively target disease-initiating cells, is a critical step toward changing the course of disease in patients with ET and MF,' said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. 'As a partner, QIAGEN has the proven expertise in companion diagnostics development and approvals needed to support our ongoing work and commitment to transforming the treatment of patients with CALR-mutant MPNs.' 'Together with Incyte we are building a multimodal companion diagnostic using a powerful technology like next-generation sequencing to facilitate highly accurate testing for several blood cancer genes at once,' said Jonathan Arnold, Vice President and Head of Partnering for Precision Diagnostics at QIAGEN. 'This new partnership strengthens our role in offering companion diagnostics for the growing number of biomarkers being discovered in onco-hematology and maximizing the clinical utility of the diagnostic for payor and patient benefit, thus supporting the work of innovative, science-driven companies like Incyte to improve patient outcomes.' About Mutations in Calreticulin (mutCALR) Calreticulin (CALR) is a protein involved in the regulation of cellular calcium levels and normal protein production. Somatic, or non-inherited, DNA mutations in the CALR gene (mutCALR) can result in abnormal protein function and lead to the development of myeloproliferative neoplasms (MPNs), i a closely related group of clonal blood cancers in which the bone marrow functions abnormally, overproducing blood cells. ii,iii Among the two types of MPNs, essential thrombocythemia (ET) and myelofibrosis (MF), mutCALR drives 25-35% of all cases. i,ii About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit QIAGEN is a pioneer in precision medicine and the leader in collaborating with pharmaceutical and biotechnology companies to develop companion diagnostics, having more than 30 master collaboration agreements with global pharmaceutical and biotechnology companies to develop and commercialize diagnostic tests. QIAGEN's offering to these companies encompasses technologies ranging from polymerase chain reaction (PCR), near-patient testing and digital PCR (dPCR) to next-generation sequencing (NGS), and sample types from liquid biopsy to tissue. It also spans disease areas from cancer to non-oncology diseases such as neurodegenerative, inflammatory, and metabolic diseases – including 16 FDA-approved PCR-based companion diagnostics. For more information about QIAGEN's efforts in precision medicine please visit About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For additional information on Incyte, please visit or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. QIAGEN Forward-Looking Statement Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the 'Risk Factors' contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission. Incyte Forward-Looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the potential for Incyte's mut-CALR targeted antibody (INCA033989) to provide a potential treatment option for patients with ET or MF, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on Incyte's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA, EMA, and other regulatory authorities; the efficacy or safety of Incyte and its partners' products; the acceptance of Incyte and its partners' products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended March 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements. Source: QIAGEN N.V. Category: Precision Medicine
Business Insider
an hour ago
- Business Insider
Grab your cooler, pack the car: The road trip calls this summer as gas prices fall and economic fears linger
Country roads, take me to vacation. The open road is a preferable getaway this summer for Americans who discovered a love for road trips during the pandemic, are feeling economic uncertainty, or want to take advantage of tumbling gas prices. Road trips also offer a degree of certainty — you won't find yourself abroad as tariffs or border policies change, or the latest flight chaos strikes. James Willamor, 45, is setting out on a 4,500-mile road trip to kick off summer. It's become a passion for him; he estimates he spends between 30 and 40 nights a year camping on both short and long trips. Depending on the length of the trip and gas prices, he spends an estimated $500 to $800 on gas, and he tries to optimize by always using a points credit card and other gas rewards programs. He also plans out meals where he can and carries a small portable refrigerator filled with meats, cheeses, fruits, and vegetables. His favorite part of hitting the road is watching the landscape gradually change, going from rivers to rolling hills to mountains. "It's a lot different than in times when I've flown somewhere and you get on the plane and you get off and you're in a totally different biome," he said. "But spending three or four days driving across and seeing the gradual change is probably my favorite part." Cheaper gas and more driving this summer Already, record numbers of Americans hit the road for the first big vacation weekend of the year, per AAA. It projected that over 1 million more Americans would be traveling by car Memorial Day Weekend compared to last year — an increase from 38.2 million auto travelers in 2024 to 39.4 million this year. The urge to stay domestic seems like it'll continue through the Fourth of July: Airbnb said that bookings within 300 miles of vacationers' origin spots are up 32% over the Fourth of July weekend compared to 2024. Enterprise Mobility, whose brands include Enterprise Rent-A-Car, National Car Rental, and Alamo, told BI that the company is seeing a year-over-year increase in expected leisure travel from their non-airport locations in both June and July — what Enterprise deemed a signal of customers leaning into road trips this summer. "People are continuing to prioritize travel, and our research shows an increased interest in road trips this summer," Bridget Long, senior vice president of North American operations at Enterprise Mobility, said in a statement. At the same time, gas prices have come down from 2022-era highs, making it more affordable to hit the road. Lillian Rafson, CEO of travel agency Pack Up + Go, which plans US-based surprise vacations — where destinations are unknown and travelers give an overview of what they're interested in — said that the last few months have seen a surge of interest in road trip packages, compared to last year. Already, 47% of vacations booked through the agency in June were road trips, compared to 27% last year. Rafson said that during times of perceived economic uncertainty, more travelers opt for her firm's minimum budget bookings rather than their more expensive offerings. She said that during last November's election season, minimum-cost bookings surged; that happened yet again in April and May. "Anecdotally, our team mentioned that we've had a few trips cancelled due to layoffs or fear of layoffs, but not a statistically significant number," Rafson said. "Overall, I think people are quietly opting for a lower-budget road trip instead of a major summer trip. But they're still traveling! Just slightly differently." Saying no to flying For some, flying might not be worth it right now, given recent stories of safety and timing concerns. "Right now, I live very close to Newark Airport, and the craziest delays are happening with the air traffic control and stuff — I mean, that alone is making people iffy about traveling," Dan Pieraccini, an avid domestic traveler and road tripper based in New Jersey, said. Some travelers are opting for road trips just because they want to; Scott Reing, 37, is planning a 2,500-mile-long road trip for his family to the Grand Canyon to commemorate his wedding anniversary. His family alternates between bigger vacations abroad and domestic trips to national parks. This year happened to be a national parks year. In theory, he said, some of the appeal of the domestic trip this time around is price, although the cost will still be hefty with the amount of time they're spending on the road. "You kind of have more control over what you're spending when you're doing a road trip versus going to an all-inclusive or going on a cruise or flying abroad," Reing said. "You really have the choice to stay in a motel or a campsite one night or two nights or 10 nights versus something else." Even so, Reing said he isn't broadly rethinking travel or travel spending; next year, he could end up somewhere abroad, like Japan. Indeed, many Americans are still opting for European or international travel this summer, with some powering through uncertainties and deciding it's worth it. But the road is still calling. Cathy Keibler, a 65-year-old retiree in Indiana, is eagerly planning her first major road trip across the country. She wants to see the country, but has no desire to fly anymore. She and her husband have a new Prius, so they're not too concerned about gas expenses and are planning to bring a cooler to mitigate food costs. Keibler also wants to get a closer view of what's happening in her own country; with unrest and uncertainty, a road trip offers an opportunity to see firsthand how that's reflected in different corners of the nation. "Part of the more idealistic reason for making this road trip is to maybe try to get in touch a little bit with really what's happening out there in the country in a way that we can't really do when we're just driving on the interstates and maybe pulling over at a McDonald's," she said.
Yahoo
an hour ago
- Yahoo
What To Expect From Lennar's (LEN) Q2 Earnings
Homebuilder Lennar (NYSE:LEN) will be announcing earnings results tomorrow after market close. Here's what investors should know. Lennar beat analysts' revenue expectations by 2% last quarter, reporting revenues of $7.63 billion, up 4.4% year on year. It was a mixed quarter for the company, with an impressive beat of analysts' EPS estimates but a miss of analysts' backlog estimates. Is Lennar a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Lennar's revenue to decline 5.5% year on year to $8.29 billion, a reversal from the 9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.94 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Lennar has missed Wall Street's revenue estimates twice over the last two years. With Lennar being the first among its peers to report earnings this season, we don't have anywhere else to look to get a hint at how this quarter will unravel for industrials stocks. However, investors in the segment have had steady hands going into earnings, with share prices flat over the last month. Lennar is down 2.3% during the same time and is heading into earnings with an average analyst price target of $132.69 (compared to the current share price of $108.64). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
